Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?
Abstract
Patients with type 2 diabetes should improve lifestyle habits combined with metformin as first pharmacological compound (in absence of contra-indications). In case of failure of metformin monotherapy (due to the progression of the disease secondary to B-cell exhaustion), another oral glucose-lowering agent should be added. Several medications may be used, with some advantages and disadvantages for each of them. The present clinical case illustrates this dilemma and should help the reasoning leading to the best pharmacological combination according to individual patient's profile.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.